Phase II trial of Baker's antifol in metastatic renal cell carcinoma: a Southwest Oncology Group Study.
Fifteen patients with metastatic renal cell carcinoma were treated with Baker's antifol at a dose schedule of 250 mg/m2 iv for 3 days every 3 weeks. One objective response was seen, and toxicity was minimal. No usefulness of Baker's antifol in the treatment of metastatic renal cell carcinoma was demonstrated.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D003967:Diarrhea / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D006098:Granulocytes; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010976:Platelet Count; D014227:Triazines / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D014227:Triazines; C012071:triazinate